title: Stage I nonseminomatous germ cell tumor of the testis: more questions than answers?
abstract: The outcome of patients with stage I nonseminomatous germ cell tumors (NSGCTs) is excellent, with 99% overall 5-year survival. If treated with orchiectomy alone, approximately 30% of patients relapse with metastatic disease. Therefore adjuvant therapy with either chemotherapy or retroperitoneal lymph node dissection (RPLND) is often recommended, despite impressive results with active surveillance alone. This article addresses the risks and benefits of each approach.
authors.affiliation: St Bartholomew's Hospital, Barts and The London NHS Trust, Charterhouse Square, London EC1A7BE, UK. Thomas.Powles@bartsandthelondon.nhs.uk
authors.forename: Thomas
authors.initials: T
authors.lastname: Powles
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D006801:Humans; D008197:Lymph Node Excision; D008297:Male; D009367:Neoplasm Staging; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D009919:Orchiectomy; D012187:Retroperitoneal Space; D013736:Testicular Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*